U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07789873) titled 'A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease' on Aug. 24.
Brief Summary: This Phase 2a study will evaluate the safety and tolerability of GAL-101 in approximately 100 participants with mild to moderate Alzheimer's disease associated with amyloid-beta pathology. Participants will be randomly assigned to receive either 1200 mg of GAL-101 salt or matching placebo tablets by mouth once daily for 28 days. Neither the participants nor the study team will know which treatment each participant receives during the study.
The study will also explore whether GAL-101 affects brain-wave activity measured u...